Abstract Cannabinoids inhibit motility and secretion in the intestine. They are now assigned the additional task of curbing excessive inflammation, suggesting that drugs targeting the endogenous cannabinoid system could be exploited for inflammatory bowel disease....
Rochester, MN: The administration of synthetic THC (aka dronabinol) decreases colonic motility compared to placebo in patients with irritable bowel syndrome (IBS), according to clinical trial data to be published in the journal Gastroenterology. Investigators at the...
The use of cannabis is common among patients with inflammatory bowel disease (IBD), according to survey data to be published in the European Journal of Gastroenterology and Hepatology. An international team of researchers from Mount Sinai Hospital in Toronto and the...
